Specialty pharmacy drugs
High-cost, complex-to-administer, or special-handling drugs requiring specialty pharmacy distribution. Includes biologics, oncology orals, hep C antivirals, hemophilia clotting factors, and PrEP.
What this class is
Specialty pharmacy drugs are typically high-cost (often >$1,000/month), require special handling (cold-chain, controlled distribution), or require complex administration (injectables, infusions). Plans often restrict these drugs to specific specialty pharmacy networks. The most common specialty pharmacy categories: biologics, oncology orals, antivirals, HIV therapies, multiple sclerosis, hemophilia, growth hormone, immune globulins.
Representative drugs
- High-cost biologics
- Oral oncology agents (kinase inhibitors, hormonal)
- Hepatitis C antivirals
- HIV antiretrovirals
- Multiple sclerosis disease-modifying therapies
- Hemophilia clotting factors
- IVIG and immune globulins
Common denial patterns
- Wrong pharmacy network (must use plan's contracted specialty pharmacy)
- Step therapy requiring older specialty drugs
- Site-of-care reductions (home infusion vs hospital infusion)
- Prior auth with specific lab evidence
- Copay accumulator on manufacturer assistance
Clinical guidelines that win appeals
- Specific to indication — varies by drug
Frequently asked questions
What is specialty pharmacy drugs?
Specialty pharmacy drugs are typically high-cost (often >$1,000/month), require special handling (cold-chain, controlled distribution), or require complex administration (injectables, infusions). Plans often restrict these drugs to specific specialty pharmacy networks. The most common specialty pharmacy categories: biologics, oncology orals, antivirals, HIV therapies, multiple sclerosis, hemophilia, growth hormone, immune globulins.
What are the common denial patterns?
Wrong pharmacy network (must use plan's contracted specialty pharmacy); Step therapy requiring older specialty drugs; Site-of-care reductions (home infusion vs hospital infusion); Prior auth with specific lab evidence; Copay accumulator on manufacturer assistance.
Which clinical guidelines support appeals?
Specific to indication — varies by drug.
Related
- Specialty biologicsHumira, Enbrel, Stelara, Skyrizi, Cosentyx, Rinvoq, Dupixent
- Cancer treatmentsChemo, immunotherapy, CAR-T, proton, PET, off-label per NCCN
- Hepatitis C curesMavyret, Epclusa, Vosevi, Harvoni — DAA appeals
- HIV PrEP & HIV treatmentTruvada, Descovy, Apretude PrEP; Biktarvy, Dovato, Cabenuva treatment
- Antifibrotic agentsPirfenidone (Esbriet), nintedanib (Ofev) for idiopathic pulmonary fibrosis (IPF) and progressive pul
- Biologic drugs (mAbs and biosimilars)Monoclonal antibodies and other biologics targeting specific immune or growth pathways. Used in rheu
- BiosimilarsFDA-approved highly-similar versions of reference biologics. Plans frequently require biosimilar use
- Direct oral anticoagulants (DOACs)Apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa), edoxaban (Savaysa). Replaced warfar
Appeal a specialty pharmacy drugs denial
Upload your denial — DenialHelp drafts a physician-ready appeal letter in five minutes with the right clinical guideline and federal regulation cited. $39 first-level, money back if we can't draft a strong appeal.
Get started →Contact: hello@denialhelp.com